Guardian Pharmacy Services enters the back half of June with fresh target-price lifts from two major firms and a short base that has been quietly rebuilding — a combination that makes the stock's next move worth watching closely.
The analyst story is the standout this week. Both Truist Securities and B of A Securities raised their price targets on GRDN this morning, June 17. Truist moved to $47 from $43. BofA matched that level, lifting from $42. Both firms kept Buy ratings. The Street consensus has effectively re-anchored around $47 — a roughly 11% premium to the current price of $42.42. That follows a steady drumbeat of target raises since March: Oppenheimer lifted to $43 in early May, Jefferies initiated at $44 in late March, and BofA initiated at $42 in late April. Every recent analyst move has been a raise or a fresh Buy, with zero downgrades in the record. Bulls cite Guardian's technology-enabled services for long-term care facilities and a vaccine economics tailwind that helped Q4 EBITDA beat estimates. Bears point to the highly fragmented LTC pharmacy landscape and reimbursement risk as the key constraints on margin expansion. The forward earnings picture looks muted — the EPS 12-month forward year-on-year growth score ranks in just the 15th percentile — and the EV/EBIT factor sits in the 20th percentile, suggesting the stock is not cheap on those measures. The P/E has expanded by about five points over the past month to 32.5x, consistent with a stock that has gained roughly 16% in that period.
Short interest tells a more nuanced story than the bullish analyst tape suggests. Bears have been adding steadily: short interest has grown 14.6% over the past month and now accounts for 8.8% of free float — a meaningful level for a healthcare services company of this size. The weekly build is modest at 1.4%, but the trend over four to six weeks is clearly directional upward. Despite that rebuild, borrow conditions remain relaxed. Availability is running at roughly 515% — well above the 52-week low of 322% — meaning there are five shares available to lend for every two currently borrowed. Cost to borrow is just 0.47%, down 8% on the week and comfortably in "low" territory. The ORTEX short score of 58.7 is elevated but has been broadly stable over the past two weeks, not flashing urgency in either direction.
Options positioning has shifted notably less defensive over the past month, and that shift itself tells a story. The put/call ratio has fallen from nearly 3.0 in early May to 1.09 today — close to a one-standard-deviation move below the 20-day average of 1.41. In plain terms, options traders have steadily rotated away from downside hedges as the stock climbed. That move broadly mirrors the 16% price gain over the past month and suggests the options market is pricing in less concern heading into the next earnings event, currently scheduled for August 5.
The ownership picture deserves a mention given its unusual shape. Bindley Capital Partners remains the dominant holder with 26% of shares, but the March 20 insider activity was the most notable in the record: the CEO Fred Burke, CFO David Morris, Bindley Capital, and several other insiders all sold on the same date at $29.68 — a coordinated secondary offering at a price now sitting 43% below current levels. Those sales were large in aggregate but are now three months old, and the stock has more than recovered. FMR (Fidelity) added nearly 2.4 million shares in Q1, an essentially new position. Wellington built its holding by 642,000 shares. T. Rowe Price added over a million shares. The institutional flow since March has been broadly accumulative from blue-chip funds, even as some insiders trimmed.
The next scheduled catalyst is the Q2 earnings print on August 5. GRDN's most recent earnings history is thin but instructive: the May 6 report produced a 2.6% one-day decline and a 4.2% five-day drawdown, while a separate May 12 reading showed a near-flat reaction. What to watch between now and August is whether the short rebuild continues toward 10% of float — the point at which borrow tightness becomes a more interesting variable — and whether the analyst consensus around $47 holds or draws additional upgrades following what the Street is already framing as a clean fundamental setup.
See the live data behind this article on ORTEX.
Open GRDN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
